EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma

Ligong Zhang, Bing Wang, Mingliang Zhang

Frontiers in Genetics · 22.07.2026 · 17

DOI: 10.3389/fgene.2026.1875148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 22.07.2026. Verfasst von Ligong Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lymph node metastasis (LNM) is a key prognostic determinant in thyroid carcinoma (THCA), yet molecular markers capturing intrinsic metastatic potential are limited.

Methods

Generalized additive models were applied to TCGA-THCA data to screen for genes with diametrically opposite expression–tumor diameter relationships between N0 and N1 patients. CENPM was subsequently validated in independent transcriptomic cohorts, spatial transcriptomics, and immunohistochemistry. Single-cell transcriptomics, in silico knockout, drug repositioning, and molecular docking were employed to dissect its immunological roles and therapeutic relevance.

Results

CENPM expression increased with tumor diameter in N0 but decreased in N1, and high CENPM was associated with poorer disease-free survival. CENPM was predominantly enriched in CD8 + naïve and effector T cells, particularly in anaplastic carcinoma. Virtual knockout predicted downstream transcriptional changes associated with lymphocyte activation, translational machinery, and immune effector pathways. Drug repositioning identified filgotinib as a candidate to reverse the CENPM-high signature, with stable CENPM–filgotinib binding confirmed by docking and molecular dynamics.

Conclusion

CENPM shows diametrically opposite expression–diameter relationships between N0 and N1 patients, suggesting a shift in biological behavior upon nodal involvement, with potential therapeutic relevance.

Schlagwörter

Stichwörter der Autor:innen

CENPMgeneralized additive modellymph node metastasissingle-cell analysisthyroid carcinoma

Autor:innen und Institutionen

  • Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.

Zitieren

APA

Zhang, L., Wang, B., & Zhang, M. (2026). CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.1875148

Vancouver

Zhang L, Wang B, Zhang M. CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.1875148

BibTeX
@article{Zhang2026,
  author = {Zhang, Ligong and Wang, Bing and Zhang, Mingliang},
  title = {CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma},
  journal = {Frontiers in Genetics},
  year = {2026},
  volume = {17},
  doi = {10.3389/fgene.2026.1875148}
}
Kostenlos starten →